Author/Authors :
bardak, handan isparta özel kariyer göz hastanesi, Turkey , günay, murat zeynep kamil kadın ve çocuk hastalıkları eğitim araştırma hastanesi - göz hastalıkları kliniği, Turkey , daldal, hatice süleyman demirel üniversitesi - tıp fakültesi - göz hastalıkları anabilim dalı, Turkey , ekim, mustafa muhterem isparta özel kariyer göz hastanesi, Turkey , bardak, yavuz isparta özel kariyer göz hastanesi, Turkey , bardak, yavuz süleyman demirel üniversitesi - tıp fakültesi - göz hastalıkları anabilim dalı, Turkey
Title Of Article :
Short term effect of combined intravitreal triamcinolone-bevacizumab with topical nepafenac treatment in refractory age related macular degeneration
Abstract :
Abstract: Aim: To investigate the efficacy and safety of topical nepafenac treatment with combined intravitreal bevacizumab (IVB)-triamcinolone acetonide (IVTA) injection In exudative age-related macular degeneration (AMD) resistant to anti-VEGF therapy. Material and Methods: Thirteen eyes of 13 patients with exudative AMD resistant to anti-VEGF therapy were included the study. IVTA (2mg 0.05ml) and IVB (1.25mg 0.05ml) combined injection was performed in patients and 3x1 nepafenac was applied topically for three months. Ocular examination of patients was performed, corrected visual acuity (CVA) and central macular thickness (CMT) measured before the treatment, 1 month and 3 months after combined injection. Results: Seven (54 %) patients were women and 6 (46 %) patients were men and their mean age was 75,23±7,93 years. Before treatment CMT was 426.15±74.31 micron and 1 month after combined injection CMT was 363.30±55.86 micron and 3 months after CMT was 310.84±43.69 micron. There was significant reduction in CMT 1 month and 3 months after injection (p 0.05) with respect to CMT before treatment. Before treatment CVA was 1.66±0.67 Log Mar and 1 month after combined injection CVA was 1.40±0.65 Log Mar and 3 months after combined injection CVA was 1,24±0,66 Log Mar. There was significant change in CVA 1 month and 3 months after injection (p 0.05) with respect to CVA before treatment. Three months after combined injection 7 (63.64 %) patients needed intravitreal injection. Conclusion: Combined IVTA-IVB injection together with topical nepafenac treatment is safe and effective procedure in exudative AMD refractory to anti-VEGF therapy.
NaturalLanguageKeyword :
Age , related macular degeneration , bevacizumab , nepafenac , triamcinolone acetonide.
JournalTitle :
Medical Journal Of Suleyman Demirel University
